Evidence map›Paper›PMID 33914767›Full record

ArticlePloS one2021

Improved transformation efficiency of group A Streptococcus by inactivation of a type I restriction modification system.

Meredith B Finn, Kathryn M Ramsey, Hunter J Tolliver, Simon L Dove, Michael R Wessels

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Epigenomics identifies three sources of DNA methylation inbioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. The group AInfection and immunity · 2025
    Article
  7. The burden of group AiScience · 2025
    Review
  8. Article
  9. Article
  10. An efficientmBio · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Characterization of theFrontiers in microbiology · 2023
    Article
  16. Article
  17. DNA Methyltransferase HsdM Induce Drug Resistance onAntibiotics (Basel, Switzerland) · 2021
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Meredith B FinnDivision of Infectious Diseases, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America.
Kathryn M RamseyDepartments of Cell and Molecular Biology and Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island, United States of America.ORCID 0000-0002-9014-4416
Hunter J TolliverDivision of Infectious Diseases, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0003-0486-4749
Simon L DoveDivision of Infectious Diseases, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America.
Michael R WesselsDivision of Infectious Diseases, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0001-7494-4723
Boston Children's Hospital · USUniversity of Rhode Island · US

Funding

IMMUNE RESPONSE TO THE GROUP A STREPTOCOCCAL CAPSULER01AI029952 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI WESSELS, MICHAEL R · 1991 to 2019
$5.6M
NIAID NIH HHS R01 AI029952
6 · The paper itself

Abstract

Streptococcus pyogenes or group A Streptococcus (GAS) is a leading cause of bacterial pharyngitis, skin and soft tissue infections, life-threatening invasive infections, and the post-infectious autoimmune syndromes of acute rheumatic fever and post-streptococcal glomerulonephritis. Genetic manipulation of this important pathogen is complicated by resistance of the organism to genetic transformation. Very low transformation efficiency is attributed to recognition and degradation of introduced foreign DNA by a type I restriction-modification system encoded by the hsdRSM locus. DNA sequence analysis of this locus in ten GAS strains that had been previously transformed with an unrelated plasmid revealed that six of the ten harbored a spontaneous mutation in hsdR, S, or M. The mutations were all different, and at least five of the six were predicted to result in loss of function of the respective hsd gene product. The unexpected occurrence of such mutations in previously transformed isolates suggested that the process of transformation selects for spontaneous inactivating mutations in the Hsd system. We investigated the possibility of exploiting the increased transformability of hsd mutants by constructing a deletion mutation in hsdM in GAS strain 854, a clinical isolate representative of the globally dominant M1T1 clonal group. Mutant strain 854ΔhsdM exhibited a 5-fold increase in electrotransformation efficiency compared to the wild type parent strain and no obvious change in growth or off-target gene expression. We conclude that genetic transformation of GAS selects for spontaneous mutants in the hsdRSM restriction modification system. We propose that use of a defined hsdM mutant as a parent strain for genetic manipulation of GAS will enhance transformation efficiency and reduce the likelihood of selecting spontaneous hsd mutants with uncharacterized genotypes.

Indexed as

Transformation, GeneticBacterial ProteinsDNA Restriction-Modification EnzymesGene Expression Regulation, BacterialGenetic LociHumansModels, MolecularMutationStreptococcal InfectionsStreptococcus pyogenesVirulenceBacterial ProteinsDNA Restriction-Modification Enzymes

Identifiers

PMID33914767
PMCPMC8084154
OpenAlexW3158423879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.